Regeneron (REGN) Stock: Why It Rose 12% on a Q3 Beat

Quick answer

Regeneron traded at $913.33 at 11:45am ET on Oct 30, 2026, up 11.5% from an $818.77 close, after a third quarter that beat on every main line. Revenue rose 36% to $5.12 billion, against about $4.56 billion expected, and non-GAAP earnings rose 70% to $20.07 a share, against about $16.08. The biggest driver was Sanofi: with the Development Balance repaid, Regeneron's share of Dupixent and Kevzara profits rose to $2.575 billion from $1.456 billion. The stock opened at $869.43, dipped to $839.08 and hit a 52-week high of $935.35 at 9:40am.

Our view: Bullish through November 30, 2026, which covers the FDA decision on cemdisiran in generalized myasthenia gravis that Regeneron expects next month. The case for the stock: the profit-share step-up is recurring, not one-time; EYLEA HD, Dupixent and Libtayo all set records; the company cut its full-year non-GAAP SG&A guide and raised its gross margin guide; and the shares trade at about 19.5 times trailing earnings after the jump. The case against: the stock now sits above the $853.63 consensus target, the old EYLEA is shrinking fast, much of the profit depends on one partner's drug, and the fourth quarter will include a $1.0 billion up-front payment that will not repeat. We lean Bullish because the earnings base has moved up for good while the price has moved by less than the earnings did. We would change the view if the FDA rejects or delays cemdisiran, if the stock gives back the gap and closes below the $869.43 open, or if Sanofi cuts its Dupixent outlook.

Regeneron daily closing price from Sep 17 to Oct 30, 2026, with the Oct 5 low, the Oct 15 UBS upgrade and the Oct 30 jump marked

Key takeaways

Regeneron traded at $913.33 at 11:45am ET on Oct 30, 2026, up 11.5% from an $818.77 close, after third-quarter revenue rose 36% to $5.1 billion and non-GAAP earnings rose 70% to $20.07 a share.
Revenue beat the roughly $4.56 billion expected and earnings beat about $16.08, helped by the first full quarter of Sanofi profit share since the Development Balance was repaid.
Dupixent sales rose 35% to $6.5 billion, EYLEA HD U.S. sales rose 62% to $699 million and Libtayo rose 51% to $550 million, while older EYLEA fell 41%.
Regeneron widened its Sanofi alliance for $1.0 billion up front, to be booked in the fourth quarter, and up to $7.0 billion in milestones, and it expects an FDA decision on cemdisiran next month.
Our view is Bullish through November 30, 2026: the beat came from recurring profit share and three growing drugs, and the stock trades at about 19.5 times trailing earnings with an FDA decision ahead.

Table of contents

Oct 30, 2026: a gap up on the third quarter
What the numbers say
The bull case
The risks
What comes next

Oct 30, 2026: a gap up on the third quarter

Regeneron reported before the open. Premarket trading began at $833.50 at 4:10am and rose to $887.00 by 8:05am. The stock opened at $869.43, fell to $839.08 in the first five minutes as the market sold off, then climbed to $935.35 by 9:40am, up 14.2%. It was $913.33 at 11:45am, on 1.4 million shares, already 2.2 times its 20-day average for a full day.

What happened:

Sanofi profit share stepped up. Sanofi collaboration revenue was $2.724 billion against $1.617 billion a year earlier. Dupixent sales, which Sanofi records, rose 35% to $6.5 billion. The CFO called it the "anticipated step-up" in the first full quarter after the Development Balance was repaid.
Three drugs set records. EYLEA HD U.S. sales rose 62% to $699 million, Libtayo rose 51% to $550 million, and Dupixent set its own high. The original EYLEA fell 41% to $400 million, so the U.S. EYLEA franchise was down 1% to $1.099 billion.
A bigger Sanofi deal. Regeneron added four next-generation, long-acting immunology antibodies to the alliance, for $1.0 billion up front, to be booked as revenue in the fourth quarter, and up to $7.0 billion in milestones.
A new approval. The FDA approved Pasatru (garetosmab) for fibrodysplasia ossificans progressiva, a rare bone disease.
Better margins. The company raised its 2026 non-GAAP gross margin guide to about 86% from 84% to 85% and cut its non-GAAP SG&A guide to $2.40 billion to $2.50 billion, from $2.50 billion to $2.60 billion. It raised non-GAAP R&D to $6.05 billion to $6.15 billion.

From the Oct 29 close, at about 11:45am:

Stock or fund	Oct 29 close	Oct 30, 11:45am	Change
Regeneron (REGN)	$818.77	$913.33	+11.5%
Eli Lilly (LLY)	$1,373.70	$1,423.14	+3.6%
Sanofi (SNY)	$43.13	$44.51	+3.2%
Vertex (VRTX)	$540.00	$556.70	+3.1%
Amgen (AMGN)	$460.73	$469.31	+1.9%
Biogen (BIIB)	$249.65	$253.32	+1.5%
Health care fund (XLV)	$184.04	$185.44	+0.8%

Large drugmakers rose as money left technology, but Regeneron rose three to seven times as far as its peers. Sanofi gained too, since the same Dupixent numbers drive its results. More of the day's swings are in today's biggest stock moves.

After the jump, RSI(14) stood at 78, the shares sat 15% above their 50-day average and 24% above their 200-day average, and the stock was 2.2% below its new 52-week high. These are context, not signals.

What the numbers say

The quarter is a reset of the earnings base. Until June, Regeneron's share of Sanofi profits was reduced to pay back its share of development costs. That ended with the second quarter, and the effect showed at once: total collaboration revenue rose to $3.0 billion from $1.97 billion. Our explainer on normalized earnings covers why a change like this matters more than a one-off beat.

Bar chart of Regeneron third-quarter 2026 sales growth by product: Dupixent 35%, EYLEA HD 62%, Libtayo 51% and the original EYLEA down 41%

On product sales, the picture is mixed. Total net product sales rose 14% to $1.8 billion. EYLEA HD is replacing the original drug, but combined U.S. EYLEA sales still slipped 1%, and the release cited "continued competitive pressures." Libtayo, the cancer drug, is now a $2.2 billion annual run rate.

At $913.33 the market value is about $94 billion. Trailing earnings put the stock at about 19.5 times, and annualizing the third quarter's $20.07 gives about $80 a share, or about 11 times. The consensus target before today was $853.63, with a range of $750 to $1,030. Our guide to forward and trailing P/E explains why an annualized quarter is a rough guide when one partner drives most of the profit.

The bull case

Recurring profit. The Sanofi step-up repeats every quarter while Dupixent grows.
Three growing drugs. EYLEA HD, Libtayo and Dupixent all grew 35% or more.
Cash and buybacks. Regeneron had $2.2 billion left on its buyback authorization at Sep 30 and declared a $0.94 quarterly dividend.
A near catalyst. The cemdisiran decision is due next month. Our guide to FDA decision dates explains how these dates move stocks.
Analyst momentum. UBS upgraded the stock to Buy on Oct 15, and TD Cowen and Canaccord kept Buy ratings in the two weeks before the report.

The risks

Partner concentration. More than half of revenue now comes from the Sanofi alliance, and Dupixent faces patent expiry in 2031, Seeking Alpha noted in its preview.
The old EYLEA. Sales fell 41% and the franchise is shrinking overall in the U.S.
A one-time fourth quarter. The $1.0 billion up-front payment will inflate fourth-quarter revenue and earnings and will make next year's comparison harder.
The price has passed the targets. The stock is about 7% above the consensus target. Our piece on estimate revisions covers how quickly targets usually follow.

What comes next

The FDA decision on cemdisiran in generalized myasthenia gravis is the next dated event, expected in November. After that come the Ordspono decision in lymphoma in February 2027 and a Libtayo dosing decision in March 2027. The fourth-quarter report in late January or early February will show the first full quarter of the new Sanofi deal.

Frequently asked questions

Why did Regeneron stock rise today?

Regeneron traded at $913.33 at 11:45am ET on Oct 30, up 11.5%, after reporting third-quarter revenue of $5.1 billion, up 36%, and non-GAAP earnings of $20.07 a share, up 70%. Both beat estimates. It also expanded its alliance with Sanofi for $1.0 billion up front.

Why did Regeneron's Sanofi revenue jump?

Regeneron repaid its share of development costs with Sanofi, called the Development Balance, by the end of the second quarter of 2026. From the third quarter that balance no longer reduces its share of profits, which rose to $2.575 billion from $1.456 billion a year earlier.

How did EYLEA do in the third quarter?

EYLEA HD U.S. net sales rose 62% to $699 million, while the original EYLEA fell 41% to $400 million as patients moved to the higher dose and competitors took share. Combined U.S. sales were $1.099 billion, down 1%.

What is the new Sanofi deal?

Regeneron added four long-acting immunology antibodies it invented to its Sanofi collaboration. It receives $1.0 billion up front, to be recognized as collaboration revenue in the fourth quarter of 2026, and can receive up to $7.0 billion more in milestones.

What is Regeneron's next catalyst?

Regeneron said it expects an FDA decision on cemdisiran in generalized myasthenia gravis next month. The FDA's decision on Ordspono in lymphoma is due in February 2027 and a Libtayo dosing decision in March 2027.

Sources

Article details

By James Whitfield, Head of Equity Research, Dombey Capital

Published October 30, 2026 · 5 min read · Event-Driven Investing